Literature DB >> 6851039

Mechanisms of angina relief after nifedipine: a hemodynamic and myocardial metabolic study.

H Emanuelsson, S Holmberg.   

Abstract

To elucidate the mechanisms of action of nifedipine in angina pectoris, 14 patients were studied before and after sublingual administration of 10 mg nifedipine. Systemic and coronary hemodynamic and myocardial metabolic measurements were taken at rest and during pacing. At the pacing rate that induced pain in the control situation, no patient experienced angina after nifedipine administration. Lactate production during control turned into extraction after nifedipine administration (p less than .05), and the double product was reduced (p less than .001). Systemic and coronary vascular resistance were reduced by 26% (p less than .001) and 19% (p less than .005), respectively. Systolic blood pressure fell from 160 +/- 29 to 127 +/- 25 mm Hg (p less than .001) and diastolic from 100 +/- 14 to 79 +/- 11 mm Hg (p less than .001). Pulmonary artery diastolic blood pressure fell from 14 +/- 4 to 10 +/- 3 mm Hg (p less than .01). When the pacing rate was further increased after nifedipine administration until pain developed, the double product and the degree of lactate production were the same as during pain before nifedipine was administered. The pacing rate was 131 +/- 12 compared with 119 +/- 13 during control (p less than .001). Both the systolic and diastolic blood pressures were still significantly reduced compared with control pacing values, 131 +/- 26 mm Hg (p less than .01) and 84 +/- 13 mm Hg (p less than .01), respectively. Our data demonstrate that the antianginal efficiency can be partly explained by afterload reduction, which decreases myocardial oxygen consumption. The data also suggest additional mechanisms, possibly an increase in collateral flow, direct dilatation of stenotic parts of epicardial arteries, or a decrease in myocardial back pressure secondary to reduced left ventricular filling pressure.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6851039     DOI: 10.1161/01.cir.68.1.124

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  Effects of nifedipine on cardiac function in patients with coronary artery disease evaluated with ambulatory radionuclide monitoring.

Authors:  H Kambara; I H Mohiuddin; N Tamaki; T Fudo; M Hayashi; R Nohara; J Konishi; C Kawai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

Review 2.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

3.  Treatment of angina pectoris with nifedipine and atenolol: efficacy and effect on cardiac function.

Authors:  I N Findlay; K MacLeod; M Ford; G Gillen; A T Elliott; H J Dargie
Journal:  Br Heart J       Date:  1986-03

4.  Effects of nicardipine on coronary blood flow, left ventricular inotropic state and myocardial metabolism in patients with angina pectoris.

Authors:  M F Rousseau; M F Vincent; P Cheron; G van den Berghe; A A Charlier; H Pouleur
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

5.  Alterations in angina threshold with nifedipine during pacing induced angina.

Authors:  P H Kramer; K Chatterjee; A Schwartz; K Swedberg; J L Rouleau; D Curran; L Blevins; W W Parmley
Journal:  Br Heart J       Date:  1984-09

6.  Modification of pacing-induced alterations in diastolic properties of the regional myocardium by nifedipine in patients with coronary artery disease.

Authors:  H Nonogi; S Sasayama; S Miyazaki; H Asanoi; K Yamanishi; C Kawai; S Eiho; M Kuwahara
Journal:  Heart Vessels       Date:  1985-11       Impact factor: 2.037

7.  [Increase in liver circulation with nifedipine].

Authors:  J Nitsch; R Kuhnen; B Lüderitz
Journal:  Klin Wochenschr       Date:  1986-10-31

8.  Intravenous nifedipine for prevention of myocardial ischaemia after coronary revascularization.

Authors:  J Y Dupuis; H J Nathan; S Laganière
Journal:  Can J Anaesth       Date:  1992-12       Impact factor: 5.063

Review 9.  Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

10.  A randomized double-blind crossover study of nicardipine and nifedipine in patients with angina pectoris and concomitant essential hypertension.

Authors:  M Metra; S Nodari; G Nordio; L Bonandi; R Raddino; P Feroldi; L Dei Cas; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.